Analysis of the ovarian serous carcinoma dataset showed that of 398 patients, amplification of TPD54 was seen in 29 (7%), amplification of Rab25 in 20 (5%), and a significant cooccurrence in 7 patients (log2 odds ratio >3, P < 0.001, and q < 0.001). Here, TPD52L2 is linked to ovarian serous carcinoma.